Flare Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $123M
Overview
A biotech developing small molecules that target transcription factors for cancer and neurological diseases.
OncologyNeuroscience
Technology Platform
The 'TF Decoder' platform uses structural and computational biology to identify druggable 'switch sites' on transcription factors for small molecule drug development.
Funding History
1Total raised:$123M
Series A$123M
Opportunities
Successfully drugging transcription factors could open up a vast new target class across oncology and neuroscience.
Risk Factors
The approach is technologically novel and unproven in the clinic, carrying high biological and development risk.
Competitive Landscape
Competes with companies developing SERDs, PROTACs, and other novel endocrine therapies in oncology, but its direct TF targeting approach is highly differentiated.